Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER-2 Positive Breast Cancer × Doxorubicin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 262 Lymphoma 183 Lymphoma, Large B-Cell, Diffuse 158 Sarcoma 127 Precursor Cell Lymphoblastic Leukemia-Lymphoma 98 Hodgkin Disease 78 Lymphoma, Non-Hodgkin 71 Burkitt Lymphoma 62 Lymphoma, Follicular 59 Leukemia 54 Ovarian Neoplasms 47 Lymphoma, Mantle-Cell 45 Triple Negative Breast Neoplasms 44 Neoplasms 44 Carcinoma, Hepatocellular 43 Multiple Myeloma 38 Neuroblastoma 36 Neoplasm Metastasis 36 Lymphoma, B-Cell 29 Lymphoma, Large-Cell, Anaplastic 28 Osteosarcoma 25 Lymphoma, T-Cell, Peripheral 24 Lymphoma, Large-Cell, Immunoblastic 23 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 22 Liposarcoma 22 Leiomyosarcoma 22 Recurrence 21 Urinary Bladder Neoplasms 20 Endometrial Neoplasms 20 Prostatic Neoplasms 19

Interventions

Trastuzumab 2 liposomal doxorubicin 1 eribulin 1 Metformin 1 Doxorubicin 1 Docetaxel 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02488564 2025-02-03

met-HEReMYTA

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Completed

HER-2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡